文献速递贫血与红细胞疾病

FERWON-IDA试验:异麦芽糖铁1000与蔗糖铁前瞻性多中心随机对照研究

A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
PubMed 文献 · Am J Hematol · 2019-07-13

FERWON-IDA是一项美国多中心随机开放标签试验,1512例缺铁性贫血患者按2:1随机接受单次1000 mg异麦芽糖铁1000或蔗糖铁200 mg静脉注射最多五次。主要安全终点(严重或重度超敏反应)两组无风险差异,主要疗效终点(第8周血红蛋白变化非劣效)达到,异麦芽糖铁组前两周血液学反应更迅速。

要点

  • 单次1000 mg异麦芽糖铁与多次蔗糖铁在严重或重度超敏反应上无风险差异。
  • 异麦芽糖铁组第8周血红蛋白变化达到非劣效,且前两周血液学反应更迅速。
  • 两组低磷血症发生率均低,心血管事件发生率分别为0.8%和1.2%(P=0.570)。

核心结论

  • 单次1000 mg异麦芽糖铁较需多次就诊的蔗糖铁带来更迅速且更显著的血液学反应,安全性特征相似,超敏反应和心血管事件发生率低。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签、对照试验,在美国开展,共纳入1512例混合病因的缺铁性贫血患者,按2:1随机分配。

主要发现

  • 严重或重度超敏反应发生率在异麦芽糖铁组为0.3%(95%CI 0.06;0.88),蔗糖铁组为0.4%(95%CI 0.05;1.45),两组无风险差异。
  • 第8周血红蛋白变化非劣效终点达到,异麦芽糖铁组前两周血液学反应显著更迅速。
  • 心血管事件发生率异麦芽糖铁组0.8% vs 蔗糖铁组1.2%(P=0.570)。
  • 两组低磷血症发生率均低。

关键数值与推荐

  • 异麦芽糖铁1000组:单次1000 mg静脉给药;蔗糖铁组:200 mg静脉注射,最多五次。
  • 共同主要安全终点为裁定严重或重度超敏反应,共同主要疗效终点为基线至第8周血红蛋白变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron deficiency anemia (IDA) is prevalent, and intravenous iron, especially if given in a single dose, may result in better adherence compared with oral iron. The present trial (FERWON-IDA) is part of the FERWON program with iron isomaltoside 1000/ferric derisomaltose (IIM), evaluating safety and efficacy of high dose IIM in IDA patients of mixed etiologies. This was a randomized, open-label, comparative, multi-center trial conducted in the USA. The IDA patients were randomized 2:1 to a single dose of 1000 mg IIM, or iron sucrose (IS) administered as 200 mg intravenous injections, up to five times. The co-primary endpoints were adjudicated serious or severe hypersensitivity reactions, and change in hemoglobin from baseline to week eight. A total of 1512 patients were enrolled. The frequency of patients with serious or severe hypersensitivity reactions was 0.3% (95% confidence interval: 0.06;0.88) vs 0.4% (0.05;1.45) in the IIM and IS group, respectively. The co-primary safety objective was met, and no risk difference was observed between groups. The co-primary efficacy endpoint of non-inferiority in hemoglobin change was met, and IIM led to a significantly more rapid hematological response in the first two weeks. The frequency of cardiovascular events was 0.8% and 1.2% in the IIM and IS group, respectively (P = .570). The frequency of hypophosphatemia was low in both groups. Iron isomaltoside administered as 1000 mg resulted in a more rapid and more pronounced hematological response, compared with IS, which required multiple visits. The safety profile was similar with a low frequency of hypersensitivity reactions and cardiovascular events.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019. PMID: 31243803. doi:10.1002/ajh.25564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。